Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Black Diamond Therapeutics Inc has a consensus price target of $15.6 based on the ratings of 5 analysts. The high is $20 issued by Raymond James on July 31, 2024. The low is $12 issued by HC Wainwright & Co. on March 18, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Stifel, and HC Wainwright & Co. on March 18, 2025, March 7, 2025, and November 6, 2024, respectively. With an average price target of $12.67 between HC Wainwright & Co., Stifel, and HC Wainwright & Co., there's an implied 658.48% upside for Black Diamond Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/18/2025 | Buy Now | 618.56% | HC Wainwright & Co. | Robert Burns42% | $11 → $12 | Maintains | Buy | Get Alert |
03/07/2025 | Buy Now | 798.2% | Stifel | Bradley Canino40% | $16 → $15 | Maintains | Buy | Get Alert |
11/06/2024 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
10/09/2024 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
10/08/2024 | Buy Now | 858.08% | Wedbush | Robert Driscoll44% | $16 → $16 | Reiterates | Outperform → Outperform | Get Alert |
09/24/2024 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
09/23/2024 | Buy Now | 798.2% | Piper Sandler | Joseph Catanzaro42% | $12 → $15 | Maintains | Overweight | Get Alert |
09/18/2024 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
09/10/2024 | Buy Now | 858.08% | Wedbush | Robert Driscoll44% | $16 → $16 | Reiterates | Outperform → Outperform | Get Alert |
09/04/2024 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
08/07/2024 | Buy Now | 858.08% | Wedbush | Robert Driscoll44% | $16 → $16 | Reiterates | Outperform → Outperform | Get Alert |
07/31/2024 | Buy Now | 1097.6% | Raymond James | Laura Prendergast23% | → $20 | Initiates | → Outperform | Get Alert |
07/03/2024 | Buy Now | 618.56% | Piper Sandler | Joseph Catanzaro42% | $12 → $12 | Maintains | Overweight | Get Alert |
06/07/2024 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
05/16/2024 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | $12 → $11 | Maintains | Buy | Get Alert |
04/08/2024 | Buy Now | 858.08% | Wedbush | Robert Driscoll44% | $10 → $16 | Maintains | Outperform | Get Alert |
03/18/2024 | Buy Now | 618.56% | HC Wainwright & Co. | Robert Burns42% | $11 → $12 | Reiterates | Buy → Buy | Get Alert |
03/13/2024 | Buy Now | 498.8% | Wedbush | Robert Driscoll44% | $10 → $10 | Reiterates | Outperform → Outperform | Get Alert |
11/22/2023 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | → $11 | Reiterates | Buy → Buy | Get Alert |
09/12/2023 | Buy Now | 498.8% | Wedbush | Robert Driscoll44% | → $10 | Reiterates | Outperform → Outperform | Get Alert |
07/14/2023 | Buy Now | 558.68% | Piper Sandler | Joseph Catanzaro42% | → $11 | Initiates | → Overweight | Get Alert |
06/30/2023 | Buy Now | 498.8% | Stifel | Bradley Canino40% | $2 → $10 | Upgrade | Hold → Buy | Get Alert |
06/28/2023 | Buy Now | 558.68% | HC Wainwright & Co. | Robert Burns42% | → $11 | Upgrade | Neutral → Buy | Get Alert |
06/27/2023 | Buy Now | 19.76% | Stifel | Bradley Canino40% | → $2 | Reiterates | Hold → Hold | Get Alert |
06/27/2023 | Buy Now | 498.8% | Wedbush | Robert Driscoll44% | $3 → $10 | Upgrade | Neutral → Outperform | Get Alert |
05/10/2023 | Buy Now | 79.64% | Wedbush | Robert Driscoll44% | → $3 | Reiterates | → Neutral | Get Alert |
03/29/2022 | Buy Now | — | Wedbush | Robert Driscoll44% | — | Downgrade | Outperform → Neutral | Get Alert |
The latest price target for Black Diamond Therapeutic (NASDAQ:BDTX) was reported by HC Wainwright & Co. on March 18, 2025. The analyst firm set a price target for $12.00 expecting BDTX to rise to within 12 months (a possible 618.56% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Black Diamond Therapeutic (NASDAQ:BDTX) was provided by HC Wainwright & Co., and Black Diamond Therapeutic maintained their buy rating.
The last upgrade for Black Diamond Therapeutics Inc happened on June 30, 2023 when Stifel raised their price target to $10. Stifel previously had a hold for Black Diamond Therapeutics Inc.
The last downgrade for Black Diamond Therapeutics Inc happened on March 29, 2022 when Wedbush changed their price target from N/A to N/A for Black Diamond Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a maintained with a price target of $11.00 to $12.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $1.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.